Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 29, 2020 - Issue 2: NASH and NAFLD: Emerging drugs, therapeutic targets and translational and clinical challenges
Submit an article Journal homepage
3,412
Views
11
CrossRef citations to date
0
Altmetric
Editorial

A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?

Herbert TilgDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University Innsbruck, Innsbruck, AustriaCorrespondence[email protected]
View further author information
,
Maria EffenbergerDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University Innsbruck, Innsbruck, AustriaView further author information
&
Timon E. AdolphDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University Innsbruck, Innsbruck, AustriaView further author information
Pages 103-106 | Received 28 Aug 2019, Accepted 14 Oct 2019, Published online: 24 Oct 2019

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Yi-Jie Mao, Miao-Miao Ying & Gang Xu. (2022) Identification of hub genes and small molecule therapeutic drugs related to simple steatosis with secondary analysis of existing microarray data. All Life 15:1, pages 921-932.
Read now

Articles from other publishers (10)

Sebastian J. Wallace, Frank Tacke, Robert F. Schwabe & Neil C. Henderson. (2022) Understanding the cellular interactome of non-alcoholic fatty liver disease. JHEP Reports 4:8, pages 100524.
Crossref
Jihad Aljabban, Michael Rohr, Saad Syed, Kamal Khorfan, Vincent Borkowski, Hisham Aljabban, Michael Segal, Mohamed Mukhtar, Mohammed Mohammed, Maryam Panahiazar, Dexter Hadley, Ryan Spengler & Erin Spengler. (2022) Transcriptome changes in stages of non-alcoholic fatty liver disease. World Journal of Hepatology 14:7, pages 1382-1397.
Crossref
Man Zhao, Huazhong Xie, Hao Shan, Zhihua Zheng, Guofeng Li, Min Li & Liang Hong. (2022) Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences 23:3, pages 1102.
Crossref
Pietro Torre, Benedetta Maria Motta, Roberta Sciorio, Mario Masarone & Marcello Persico. (2021) Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System. Frontiers in Medicine 8.
Crossref
Natalia Zhelezniakova & Anastasiia Rozhdestvenska. (2021) IL-1β and IL-10: diagnostic and prognostic potential of cytokines in the assessment of progression of non-alcoholic fatty liver disease in patients with hypertension. EUREKA: Health Sciences:5, pages 17-26.
Crossref
Melisa KozaczekWalter BottjeByungwhi KongDiyana AlbatainehReza Hakkak. (2021) A Comparison of Short- and Long-Term Soy Protein Isolate Intake and Its Ability to Reduce Liver Steatosis in Obese Zucker Rats Through Modifications of Genes Involved in Inflammation and Lipid Transport. Journal of Medicinal Food 24:9, pages 1010-1016.
Crossref
Olivia Wegrzyniak, Maria Rosestedt & Olof Eriksson. (2021) Recent Progress in the Molecular Imaging of Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences 22:14, pages 7348.
Crossref
Mohammad Ghanbari, Salar Momen Maragheh, Aida Aghazadeh, Seyed Reza Mehrjuyan, Bashdar Mahmud Hussen, Mahdi Abdoli Shadbad, Narges Dastmalchi & Reza Safaralizadeh. (2021) Interleukin-1 in obesity-related low-grade inflammation: From molecular mechanisms to therapeutic strategies. International Immunopharmacology 96, pages 107765.
Crossref
Dániel Kucsera, Viktória E. Tóth, Dorottya Gergő, Imre Vörös, Zsófia Onódi, Anikó Görbe, Péter Ferdinandy & Zoltán V. Varga. (2021) Characterization of the CDAA Diet-Induced Non-alcoholic Steatohepatitis Model: Sex-Specific Differences in Inflammation, Fibrosis, and Cholesterol Metabolism in Middle-Aged Mice. Frontiers in Physiology 12.
Crossref
Christopher R. Shepard. (2021) TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism. Frontiers in Endocrinology 11.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.